Releases - Genovis AB

View:
 

Found press releases

 

Genovis rights issue oversubscribed

4/22/2013 5:17 AM EST
The issue was subscribed for SEK 15,129, 289, which it was oversubscribed by 10%.
Of the total issue volume of 3,945,189 shares, 77% were subscribed for with preferential rights. The rights issue raised about SEK 13.8 million before issue expenses for Genovis. Statements of account will be sent on April 23, 2013, to allot shares subscribed for without preferential rights.

INTERIM REPORT JANUARY – MARCH 2013

4/16/2013 2:10 AM EST
January–March · Net sales increased by 102 percent to SEK 1,906k (944k). · Loss after financial items was SEK 3,957k (loss: 4,008k). · Comprehensive income was a loss of SEK 3,946k (loss: 3,970k). · Comprehensive income per share basic and diluted totaled SEK -0.33 (-0.57). · Cash flow from operating activities during the period was SEK -4,429k (-2,871k). · Cash and cash equivalents at the end of...

Genovis to publish Q1 2013 report ahead of schedule

4/10/2013 6:42 AM EST
The Interim Report for January-March, which was to be announced on April 24, will be published ahead of schedule. The new publication date for the report is April 16, 2013.

Genovis’ 2012 Annual Report Published

4/9/2013 7:59 AM EST
Genovis’ 2012 annual report has been published and is available on the Genovis website on the page with financial reports, as well as the page with documents for the 2013 annual general meeting. The English version of the annual report is expected to be published shortly.
The printed annual report can be ordered from the company: Telephone +46 (0)46-10 12 30 E-mail  

Genovis receives SEK 1.575 million from VINNOVA

3/26/2013 6:21 AM EST
VINNOVA (Swedish Agency for Innovation Systems) chose to support the project “Nanoparticles in movement serve as contrast agents in medical ultrasound,” which Genovis runs together with Associate Professor Tomas Jansson’s research group at the Department of Measurement Technology and Industrial Electrical Engineering, Lund Institute of Technology (LTH). So far the project has resulted in a contrast agent and a...

Notice of Annual General Meeting of Genovis AB (publ)

3/21/2013 7:10 AM EST
Shareholders of GENOVIS AB (publ) are hereby summoned to the Annual General Meeting (“the Meeting”) to be held on Thursday, April 25, 2013, at 5:00 p.m. at Scheelevägen 22, Lund, Sweden. Registration for the Meeting will commence at 16:30 pm.

Agenda

1. Opening of the meeting.
2. Election of chairman for the meeting.
3. Preparation and approval of voting list.
4. Approval of the agenda. 
5. Election of two...

Genovis signs agreement on projects for major pharmaceutical company

3/20/2013 5:44 AM EST
The one-year development project agreement on behalf of a customer is worth about USD 100,000. The project will adapt Genovis’ products from the protein characterization portfolio to the customer’s technology platform.
“We look forward to launching this initiative together with our customer. This project demonstrates the interest in Genovis’ unique products and is a recognition of our skills and experience in...

YEAR-END REPORT JANUARY-DECEMBER 2012

2/28/2013 3:52 AM EST
Fourth quarter 2012 (compared with the same period 2011) · Net sales increased by 88% to SEK 2,017k (1,071k). · Operating loss before depreciation, amortization and impairment was SEK 4,335k (loss: 3,333k). · Loss after financial items was SEK 8,465k (loss: 3,956k)*. · Comprehensive income for the period was a loss of SEK 8,331k (loss: 3,835k)*. · Comprehensive income per share basic and diluted totaled...

Genovis’ Board of Directors decides on rights issue

2/19/2013 5:47 AM EST
Sales of products from Genovis’ protein engineering portfolio have shown a steady increase of about 100% percent annually. Genovis aims to maintain this growth rate during 2013 and thus approach a positive cash flow. Achieving this goal requires financing of about SEK 7 million. At the same time, because the Board of Directors at Genovis wishes to increase transparency and clarity when communicating about...
 

Continued strong sales in third quarter

11/13/2012 4:46 AM EST
Third quarter 2012 (compared with the same period 2011) · Net sales increased by 152% to SEK 1,972k (784k). · Loss after financial items was SEK 3,259k (loss: 3,018k). · Comprehensive income per share basic and diluted totaled SEK -0.27 (-0.43). · Cash flow from operating activities during the period was SEK -3,614k (-3,040k). · Cash and cash equivalents at the end of the period totaled SEK 10,917k...

Genovis AB

The Group consists of Genovis AB and the fully owned subsidiary Eijdo research AB. Genovis develops and sells innovative technologies from two unique product portfolios. The first involves nanotechnology in new contrast ...

View more


  CONTACT